- Home
- BSET vs NMRA Comparison
BSET vs NMRA Comparison
Compare BSET & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSET
- NMRA
- Stock Information
- Founded
- BSET 1902
- NMRA 2019
- Country
- BSET United States
- NMRA United States
- Employees
- BSET N/A
- NMRA N/A
- Industry
- BSET Home Furnishings
- NMRA
- Sector
- BSET Consumer Discretionary
- NMRA
- Exchange
- BSET Nasdaq
- NMRA Nasdaq
- Market Cap
- BSET 135.8M
- NMRA 121.0M
- IPO Year
- BSET 1987
- NMRA 2023
- Fundamental
- Price
- BSET $15.20
- NMRA $0.77
- Analyst Decision
- BSET
- NMRA Buy
- Analyst Count
- BSET 0
- NMRA 8
- Target Price
- BSET N/A
- NMRA $9.29
- AVG Volume (30 Days)
- BSET 71.0K
- NMRA 1.3M
- Earning Date
- BSET 07-09-2025
- NMRA 08-05-2025
- Dividend Yield
- BSET 5.61%
- NMRA N/A
- EPS Growth
- BSET N/A
- NMRA N/A
- EPS
- BSET N/A
- NMRA N/A
- Revenue
- BSET $325,531,000.00
- NMRA N/A
- Revenue This Year
- BSET $2.22
- NMRA N/A
- Revenue Next Year
- BSET $3.28
- NMRA N/A
- P/E Ratio
- BSET N/A
- NMRA N/A
- Revenue Growth
- BSET N/A
- NMRA N/A
- 52 Week Low
- BSET $12.11
- NMRA $0.61
- 52 Week High
- BSET $19.67
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- BSET 44.00
- NMRA 48.68
- Support Level
- BSET $14.13
- NMRA $0.75
- Resistance Level
- BSET $16.22
- NMRA $0.85
- Average True Range (ATR)
- BSET 0.68
- NMRA 0.11
- MACD
- BSET -0.07
- NMRA -0.01
- Stochastic Oscillator
- BSET 47.77
- NMRA 9.14
About BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.